These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 22547687)

  • 21. Phosphoproteomic analysis of mouse thymoma cells treated with tributyltin oxide: TBTO affects proliferation and energy sensing pathways.
    Osman AM; van Loveren H
    Toxicol Sci; 2012 Mar; 126(1):84-100. PubMed ID: 22174045
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Suppression of RAF/MEK or PI3K synergizes cytotoxicity of receptor tyrosine kinase inhibitors in glioma tumor-initiating cells.
    Shingu T; Holmes L; Henry V; Wang Q; Latha K; Gururaj AE; Gibson LA; Doucette T; Lang FF; Rao G; Yuan L; Sulman EP; Farrell NP; Priebe W; Hess KR; Wang YA; Hu J; Bögler O
    J Transl Med; 2016 Feb; 14():46. PubMed ID: 26861698
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Parallel signaling pathways in endothelin-1-induced proliferation of U373MG astrocytoma cells.
    He S; Dibas A; Yorio T; Prasanna G
    Exp Biol Med (Maywood); 2007 Mar; 232(3):370-84. PubMed ID: 17327470
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PAK signalling drives acquired drug resistance to MAPK inhibitors in BRAF-mutant melanomas.
    Lu H; Liu S; Zhang G; Bin Wu ; Zhu Y; Frederick DT; Hu Y; Zhong W; Randell S; Sadek N; Zhang W; Chen G; Cheng C; Zeng J; Wu LW; Zhang J; Liu X; Xu W; Krepler C; Sproesser K; Xiao M; Miao B; Liu J; Song CD; Liu JY; Karakousis GC; Schuchter LM; Lu Y; Mills G; Cong Y; Chernoff J; Guo J; Boland GM; Sullivan RJ; Wei Z; Field J; Amaravadi RK; Flaherty KT; Herlyn M; Xu X; Guo W
    Nature; 2017 Oct; 550(7674):133-136. PubMed ID: 28953887
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Src inhibitors, PP2 and dasatinib, increase retinoic acid-induced association of Lyn and c-Raf (S259) and enhance MAPK-dependent differentiation of myeloid leukemia cells.
    Congleton J; MacDonald R; Yen A
    Leukemia; 2012 Jun; 26(6):1180-8. PubMed ID: 22182854
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Importance of MEK-1/-2 signaling in monocytic and granulocytic differentiation of myeloid cell lines.
    Miranda MB; McGuire TF; Johnson DE
    Leukemia; 2002 Apr; 16(4):683-92. PubMed ID: 11960350
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Proteomics analysis of protein kinases by target class-selective prefractionation and tandem mass spectrometry.
    Wissing J; Jänsch L; Nimtz M; Dieterich G; Hornberger R; Kéri G; Wehland J; Daub H
    Mol Cell Proteomics; 2007 Mar; 6(3):537-47. PubMed ID: 17192257
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Proteomics of resistance to Notch1 inhibition in acute lymphoblastic leukemia reveals targetable kinase signatures.
    Franciosa G; Smits JGA; Minuzzo S; Martinez-Val A; Indraccolo S; Olsen JV
    Nat Commun; 2021 May; 12(1):2507. PubMed ID: 33947863
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phosphoproteomic analysis reveals PAK2 as a therapeutic target for lapatinib resistance in HER2-positive breast cancer cells.
    Chang Y; Park KH; Lee JE; Han KC
    Biochem Biophys Res Commun; 2018 Oct; 505(1):187-193. PubMed ID: 30243723
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Systemic analysis of tyrosine kinase signaling reveals a common adaptive response program in a HER2-positive breast cancer.
    Schwill M; Tamaskovic R; Gajadhar AS; Kast F; White FM; Plückthun A
    Sci Signal; 2019 Jan; 12(565):. PubMed ID: 30670633
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Activation of the MEK-S6 pathway in high-grade ovarian cancers.
    Ventura AP; Radhakrishnan S; Green A; Rajaram SK; Allen AN; O'Briant K; Schummer M; Karlan B; Urban N; Tewari M; Drescher C; Knudsen BS
    Appl Immunohistochem Mol Morphol; 2010 Dec; 18(6):499-508. PubMed ID: 20661131
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Akt inhibitors MK-2206 and nelfinavir overcome mTOR inhibitor resistance in diffuse large B-cell lymphoma.
    Petrich AM; Leshchenko V; Kuo PY; Xia B; Thirukonda VK; Ulahannan N; Gordon S; Fazzari MJ; Ye BH; Sparano JA; Parekh S
    Clin Cancer Res; 2012 May; 18(9):2534-44. PubMed ID: 22338016
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inhibition of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway but not the MEK/ERK pathway attenuates laminin-mediated small cell lung cancer cellular survival and resistance to imatinib mesylate or chemotherapy.
    Tsurutani J; West KA; Sayyah J; Gills JJ; Dennis PA
    Cancer Res; 2005 Sep; 65(18):8423-32. PubMed ID: 16166321
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Integration of conventional quantitative and phospho-proteomics reveals new elements in activated Jurkat T-cell receptor pathway maintenance.
    Jouy F; Müller SA; Wagner J; Otto W; von Bergen M; Tomm JM
    Proteomics; 2015 Jan; 15(1):25-33. PubMed ID: 25348772
    [TBL] [Abstract][Full Text] [Related]  

  • 35. ERK inhibition overcomes acquired resistance to MEK inhibitors.
    Hatzivassiliou G; Liu B; O'Brien C; Spoerke JM; Hoeflich KP; Haverty PM; Soriano R; Forrest WF; Heldens S; Chen H; Toy K; Ha C; Zhou W; Song K; Friedman LS; Amler LC; Hampton GM; Moffat J; Belvin M; Lackner MR
    Mol Cancer Ther; 2012 May; 11(5):1143-54. PubMed ID: 22402123
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inference of kinase-signaling networks in human myeloid cell line models by Phosphoproteomics using kinase activity enrichment analysis (KAEA).
    Hallal M; Braga-Lagache S; Jankovic J; Simillion C; Bruggmann R; Uldry AC; Allam R; Heller M; Bonadies N
    BMC Cancer; 2021 Jul; 21(1):789. PubMed ID: 34238254
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cotargeting signaling pathways driving survival and cell cycle circumvents resistance to Kit inhibitors in leukemia.
    Buet D; Gallais I; Lauret E; Denis N; Lombard B; Guillonneau F; Kosmider O; Loew D; Dusanter-Fourt I; Guillouf C; Mayeux P; Moreau-Gachelin F
    Blood; 2012 May; 119(18):4228-41. PubMed ID: 22438255
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MEK inhibitors induce Akt activation and drug resistance by suppressing negative feedback ERK-mediated HER2 phosphorylation at Thr701.
    Chen CH; Hsia TC; Yeh MH; Chen TW; Chen YJ; Chen JT; Wei YL; Tu CY; Huang WC
    Mol Oncol; 2017 Sep; 11(9):1273-1287. PubMed ID: 28632938
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phosphoproteomics in cancer.
    Harsha HC; Pandey A
    Mol Oncol; 2010 Dec; 4(6):482-95. PubMed ID: 20937571
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Leptin stimulates ovarian cancer cell growth and inhibits apoptosis by increasing cyclin D1 and Mcl-1 expression via the activation of the MEK/ERK1/2 and PI3K/Akt signaling pathways.
    Chen C; Chang YC; Lan MS; Breslin M
    Int J Oncol; 2013 Mar; 42(3):1113-9. PubMed ID: 23354006
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.